From clinical exosome analysis to engineered therapy: miR-21-5p-Enriched exosomes reverse thin endometrium via the YAP1 pathway
Quick Facts
- Publication title: From clinical exosome analysis to engineered therapy: miR-21-5p-Enriched exosomes reverse thin endometrium via the YAP1 pathway
- Journal: Biomaterials
- Year: 2026
- DOI: 10.1016/j.biomaterials.2026.124271
- PMID/PMCID: 42119168
Research overview
Thin endometrium (TE) is associated with reduced pregnancy rates and adverse obstetric outcomes. This work identifies novel diagnostic biomarkers and pioneered an innovative therapeutic approach, thereby offering a potential strategy for improving the clinical management of TE.
Key findings
Thin endometrium (TE) is associated with reduced pregnancy rates and adverse obstetric outcomes.
While current interventions including hysteroscopic adhesiolysis and hormonal regimens offer partial solutions, functional restoration remains challenging due to the elusive pathogenesis of TE.
5%) in TE-derived UF-Exo that critically underpins disease progression.
Leveraging these insights, a miRNA-reprogramming therapeutics is established based on engineered human umbilical cord mesenchymal stem cell-derived exosome (hUCMSCs-Exo) that precisely orchestrates endometrial cellular proliferation and angiogenic processes.
Echo Biotech Role
Echo Biotech contributed cargo loading; the study also used or cited ExoLoad®.
Related platforms: Echosome®, Research Reagents & Tools
Related services and capabilities: Small RNA / Cargo Loading, Research Reagent / Product Supply
Related products or reagents: ExoLoad® Nucleic Acid Loading Kit
References
Original publication: From clinical exosome analysis to engineered therapy: miR-21-5p-Enriched exosomes reverse thin endometrium via the YAP1 pathway Biomaterials. 2026. DOI: 10.1016/j.biomaterials.2026.124271. PMID/PMCID: 42119168.